Table 1.
ctDNA analysis | Tumor-tissue analysis SoC |
Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | |||
---|---|---|---|---|---|---|---|---|
KRAS mut | NRAS mut | WT | ||||||
BEAMing | KRAS mut | 40 | 0 | 6 | 89 | 90 | 84 | 93 |
NRAS mut | 0 | 8 | 3 | |||||
WT | 4 | 2 | 83 | |||||
Total | 44 | 10 | 92 | |||||
Tumor-tissue analysis BEAMinga | 85 | 91 | 89 | 88 | ||||
BEAMing | KRAS mut | 42 | 0 | 4 | ||||
NRAS mut | 0 | 9 | 2 | |||||
WT | 7 | 2 | 64 | |||||
Total | 49 | 11 | 70 | |||||
Tumor-tissue analysis | Tumor-tissue analysis SoC | 94 | 88 | 85 | 96 | |||
BEAMing | KRAS mut | 42 | 0 | 7 | ||||
NRAS mut | 0 | 9 | 2 | |||||
WT | 2 | 1 | 67 | |||||
Total | 44 | 10 | 76 |
Tumor-tissue analysis with BEAMing was carried out in 130 samples.
WT, wild type; SoC, standard of care; ctDNA, circulating tumor DNA; PPV, positive predictive value; NPV, negative predictive value.